Outlook Therapeutics, Inc.
OTLKNasdaq
$1.39
↓ -4.8%Jul 17 close · end-of-day
Price
1Y↓ -42.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$113.8M
Enterprise Value
$106.0M
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$61.0M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
210.2%
ROIC
—
Debt / Equity
—
Net Cash
$7.7M
Return 1Y
-39.8%
Company profile
Outlook Therapeutics, Inc. focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
- CEO
- C. Russell Trenary
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 20
- Headquarters
- New Jersey
- Website
- outlooktherapeutics.com
Earnings
OTLK Q2 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.05↓ -96.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $1.4M |
| Gross profit | — | — | — | — | — | $57,205.00 |
| Operating income | -$36.8M | -$51.7M | -$63.1M | -$53.1M | -$71.7M | -$67.1M |
| Net income | -$35.2M | -$53.2M | -$66.1M | -$59.0M | -$75.4M | -$62.4M |
| Diluted EPS | -$0.67 | -$0.35 | -$0.31 | -$4.72 | -$4.06 | -$1.79 |
| Operating cash flow | -$31.8M | -$54.3M | -$56.7M | -$43.0M | -$68.8M | -$51.8M |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | 4.0% |
| Operating margin | — | — | — | — | — | -4744.3% |
| Net margin | — | — | — | — | — | -4416.2% |
| Line item | Q3 '24 | Q4 '24 | Q1 '24 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '25 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $1.5M | — | — | — |
| Gross profit | — | — | — | — | $1.1M | — | -$1.2M | -$21,888.00 |
| Operating income | -$19.6M | -$22.9M | -$21.6M | -$12.4M | -$15.7M | -$17.3M | -$13.5M | -$14.0M |
| Net income | $44.4M | $5.7M | $17.4M | -$46.4M | -$20.2M | -$13.3M | -$23.1M | -$4.5M |
| Diluted EPS | -$0.89 | $5.70 | $0.72 | -$1.50 | -$0.55 | -$0.46 | -$0.38 | -$0.05 |
| Operating cash flow | -$19.5M | -$17.0M | -$11.0M | -$16.6M | -$11.9M | -$12.4M | -$14.9M | -$7.8M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | 70.8% | — | — | — |
| Operating margin | — | — | — | — | -1046.2% | — | — | — |
| Net margin | — | — | — | — | -1338.8% | — | — | — |
Company news
Jun 17, 2026
Jun 16, 2026
- 34d agoOutlook Therapeutics (OTLK) Stock After FDA Review Win Is The Valuation Case Already Priced Infinance.yahoo.com
- 34d agoOTLK Stock Soars 28% After FDA Sets July Date For Lytenava Decisionstocktwits.com
- 34d agoOutlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a Treatment for Wet AMDfinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-02 | Haddadin Yezan Munther | Buy | 29,000 | $0.83 | $24,145.40 | filing |
| 2026-05-28 | Sukhtian Ghiath M. | Buy | 8,539,709 | $0.59 | $5.0M | filing |
| 2026-05-27 | Sukhtian Faisal Ghiath | Buy | 122,174 | $0.41 | $50,005.82 | filing |
| 2026-05-26 | HILZINGER KURT J | Buy | 400,000 | $0.44 | $176,520.00 | filing |
| 2026-05-26 | Haddadin Yezan Munther | Buy | 34,000 | $0.44 | $14,960.00 | filing |
| 2026-05-26 | THURMAN RANDY H | Buy | 5,000 | $0.43 | $2,145.00 | filing |
Latest 6 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.